Captopril suppresses hepatic mammalian target of rapamycin cell signaling and biomarkers of inflammation and oxidative stress in thioacetamide-induced hepatotoxicity in rats

References

• Abareshi, A., et al., 2016a. Lipopolysaccharide-induced spatial memory and synaptic plasticity impairment is preventable by captopril. Advances in medicine, 2016, 7676512.
   PubMedGoogle Scholar
• Abareshi, A., et al., 2016b. The effects of captopril on lipopolysaccharide induced learning and memory impairments and the brain cytokine levels and oxidative damage in rats. Life sciences, 167, 46–56.
   PubMed Web of Science ®Google Scholar
• Ackerman, Z., et al., 2005. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension, 45(5), 1012–1018.
   PubMed Web of Science ®Google Scholar
• Al-Ani, B., et al., 2010. Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells. Hypertension, 55(3), 689–697.
   PubMed Web of Science ®Google Scholar
• Aldahmash, B.A. and El-Nagar, D.M., 2016. Antioxidant effects of captopril against lead acetate-induced hepatic and splenic tissue toxicity in Swiss albino mice. Saudi journal of biological sciences, 23(6), 667–673.
   PubMed Web of Science ®Google Scholar
• Azizi-Malekabadi, H., et al., 2008. The effect of captopril on inflammation-induced liver injury in male rats. Toxin reviews. doi:https://doi.org/10.1080/15569543.2018.1517802.
   Google Scholar
• Beheshti, F., et al., 2019. Protective effect of aminoguanidine against lipopolysaccharide-induced hepatotoxicity and liver dysfunction in rat. Drug and chemical toxicology, 29, 1–7.
   Web of Science ®Google Scholar
• Boskabadi, J., et al., 2018. The effect of captopril on lipopolysaccharide-induced lung inflammation. Experimental Lung Research, 44(4–5), 191–200.
   PubMed Web of Science ®Google Scholar
• Boskabadi, J., et al., 2019. Immunomodulatory properties of captopril, an ACE inhibitor, on LPS-induced lung inflammation and fibrosis as well as oxidative stress. Inflammopharmacology, 27(3), 639–647.
   PubMed Web of Science ®Google Scholar
• Bzowej, N., et al., 2011. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transplantation, 17(5), 528–538.
   PubMed Web of Science ®Google Scholar
• Cichoz-Lach, H. and Michalak, A., 2014. Oxidative stress as a crucial factor in liver diseases. World journal of gastroenterology, 20, 8082–8091.
   PubMed Web of Science ®Google Scholar
• Cudmore, M., et al., 2007. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation, 115(13), 1789–1797.
   PubMed Web of Science ®Google Scholar
• Czaja, A.J., 2014. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World journal of gastroenterology, 20(10), 2515–2532.
   PubMed Web of Science ®Google Scholar
• El-Ashmawy, N.E., et al., 2018. Anti-inflammatory and antioxidant effects of captopril compared to methylprednisolone in L-arginine-induced acute pancreatitis. Digestive diseases and sciences, 63(6), 1497–1505.
   PubMed Web of Science ®Google Scholar
• El-Khatib, A.S. and Mansour, M.A., 2001. Prior treatment with captopril attenuates carbon tetrachloride-induced liver injury in mice. Research communications in molecular pathology and pharmacology, 110, 3–16.
   PubMed Web of Science ®Google Scholar
• El-Mezayen, N.S., et al., 2017. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: a novel strategy with potent efficacy in experimental liver fibrosis. Journal of controlled release, 266, 226–237.
   PubMed Web of Science ®Google Scholar
• Friedman, S.L., 2003. Liver fibrosis – from bench to bedside. Journal of hepatology, 38, 38–53.
   PubMed Web of Science ®Google Scholar
• Halperin, R.O., et al., 2006. Dyslipidemia and the risk of incident hypertension in men. Hypertension, 47(1), 45–50.
   PubMed Web of Science ®Google Scholar
• Hu, J., et al., 2017. Hypoxia inducible factor-1alpha mediates the profibrotic effect of albumin in renal tubular cells. Scientific reports, 7(1), 017–15972.
   PubMed Web of Science ®Google Scholar
• Huang, Y.H., et al., 2006. Therapeutic effect of interleukin-10 on CCl4-induced hepatic fibrosis in rats. World journal of gastroenterology, 12(9), 1386–1391.
   PubMed Web of Science ®Google Scholar
• Jonsson, J.R., et al., 2001. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology, 121(1), 148–155.
   PubMed Web of Science ®Google Scholar
• Karimian, G., et al., 2008. Attenuation of hepatic fibrosis through captopril and enalapril in the livers of bile duct ligated rats. Biomedicine & pharmacotherapy, 62(5), 312–316.
   PubMed Web of Science ®Google Scholar
• Li, S., et al., 2015. The role of oxidative stress and antioxidants in liver diseases. International journal of molecular sciences, 16(11), 26087–26124.
   PubMed Web of Science ®Google Scholar
• Liang, Z., et al., 2017. AMPK: a novel target for treating hepatic fibrosis. Oncotarget, 8, 62780–62792.
   PubMedGoogle Scholar
• Liedtke, C., et al., 2013. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis & tissue repair, 6(1), 19–1536.
   PubMedGoogle Scholar
• Zhong, L., et al., 2015. Protective effect of fu-qi granule on carbon tetrachloride-induced liver fibrosis in rats. World journal of pharmacology, 9, 227–235.
   Google Scholar
• Loloi, J., et al., 2018. Angiotensin-(1-7) contributes to insulin-sensitizing effects of angiotensin converting enzyme inhibition in obese mice. American journal of physiology-endocrinology and metabolism, 315, E1204–E1211.
   PubMed Web of Science ®Google Scholar
• Masoud, G.N. and Li, W., 2015. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta pharmaceutica sinica B, 5(5), 378–389.
   PubMed Web of Science ®Google Scholar
• Morio, L.A., et al., 2001. Distinct roles of tumor necrosis factor-alpha and nitric oxide in acute liver injury induced by carbon tetrachloride in mice. Toxicology and applied pharmacology, 172(1), 44–51.
   PubMed Web of Science ®Google Scholar
• Neef, M., et al., 2006. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. Journal of hepatology, 45(6), 786–796.
   PubMed Web of Science ®Google Scholar
• Nouchi, T., et al., 1991. Appearance of alpha-smooth-muscle-actin-positive cells in hepatic fibrosis. Liver, 11(2), 100–105.
   PubMedGoogle Scholar
• Park, S.Y., et al., 2010. Differential expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in thioacetamide-induced chronic liver injury. Journal of korean medical science, 25(4), 570–576.
   PubMed Web of Science ®Google Scholar
• Roderfeld, M., et al., 2006. Cytokine blockade inhibits hepatic tissue inhibitor of metalloproteinase-1 expression and up-regulates matrix metalloproteinase-9 in toxic liver injury. Liver international, 26(5), 579–586.
   PubMed Web of Science ®Google Scholar
• Shan, L., et al., 2016. mTOR overactivation in mesenchymal cells aggravates CCl4- induced liver fibrosis. Scientific reports, 6(1), 36037.
   PubMed Web of Science ®Google Scholar
• Tuncer, I., et al., 2003. Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. Experimental and toxicologic pathology, 55, 159–166.
   PubMed Web of Science ®Google Scholar
• Wallace, M.C., et al., 2015. Standard operating procedures in experimental liver research: thioacetamide model in mice and rats. Laboratory animals, 49(1_suppl), 21–29.
   PubMed Web of Science ®Google Scholar
• Wang, W., et al., 2014. Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2. PLoS One, 9(1), e83908.
   PubMed Web of Science ®Google Scholar
• Wu, Y.L., et al., 2016. Cucurbitacin E ameliorates hepatic fibrosis in vivo and in vitro through activation of AMPK and blocking mTOR-dependent signaling pathway. Toxicology letters, 258, 147–158.
   PubMed Web of Science ®Google Scholar
• Yao, Q., et al., 2013. Curcumin ameliorates intrahepatic angiogenesis and capillarization of the sinusoids in carbon tetrachloride-induced rat liver fibrosis. Toxicology letters, 222(1), 72–82.
   PubMed Web of Science ®Google Scholar
• Yu, Q.H., et al., 2016. Captopril pretreatment protects the lung against severe acute pancreatitis induced injury via inhibiting angiotensin II production and suppressing Rho/ROCK pathway. The kaohsiung journal of medical sciences, 32(9), 439–445.
   PubMed Web of Science ®Google Scholar
• Zhao, Y., et al., 2014. Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1alpha through mTOR-dependent pathway. Fitoterapia, 99, 318–327.
   PubMed Web of Science ®Google Scholar